2016 American Transplant Congress
Where Are the KDPI 0-20% Kidneys Going in the New KAS? A Major Allocation Shift.
1Univ Hosp Case Med Ctr, Cleveland, OH; 2Emory Univ, Atlanta, GA; 3UNOS, Richmond, VA.
The introduction of KAS in December 2014 marked an effort to incorporate a longevity metrics into deceased organ allocation by prioritizing retrieved kidneys with the…2016 American Transplant Congress
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.
1UNOS, Richmond, VA; 2Emory Univ, Atlanta, GA; 3Univ Hosp Case Med Ctr, Cleveland, OH.
Background: Kidney discard rates increased by 10% -- from 18.3% to 20.2% (p=0.001) -- during the first 7 months of KAS but returned to pre-KAS…2016 American Transplant Congress
Kidney Donor Profile Index Trend Analyses.
Surgery, Duke University Medical Center, Durham, NC.
IntroductionIn spite of improved outcomes associated with the usage of extended criteria donor (ECD) kidneys, the number of kidney transplants (KT) using this donor population…2016 American Transplant Congress
Use of Small (<10kg) Kidney Donors in the US.
The supply of kidneys for transplant continues to exceed the demand. Efforts to expand the donor pool have led to interest in small pediatric kidney…2016 American Transplant Congress
Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals.
The introduction of interferon-free direct-acting antivirals(DAAs) in December 2013 dramatically improved outcomes for individuals with Hepatitis C. The impacts of these therapies on utilization and…2016 American Transplant Congress
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.
Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…2016 American Transplant Congress
DAAs Rapidly Clear HCV Viremia in Recipients of HCV+ Donor Kidneys.
Purpose: Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C (HCV) in both general and liver transplant populations. However, data in kidney transplant…2016 American Transplant Congress
Long-Term Death-Censored Graft Loss in the DeKAF Study.
The aim of the Deterioration of Kidney Allograft Function study (DeKAF) was to identify and assess the pathologies of troubled kidney grafts, that is, those…2016 American Transplant Congress
Post-Transplant Monitoring of Donor-Specific Anti-HLA Antibodies and Their Characteristics Improves Risk Stratification of Kidney Allograft Loss.
Circulating donor-specific anti-HLA antibodies (DSA) are associated with allograft failure in solid-organ transplantation. We investigated the pathogenic characteristics of DSA that may improve risk prediction…2016 American Transplant Congress
Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction.
*contributed equallyIntroduction Integrity of the microvasculature is critical for long term survival after solid organ transplantation. We hypothesize that biomarkers of endothelial injury and repair…
American Transplant Congress abstracts